Gilead Sciences has completed its acquisition of Arcellx, moving to consolidate ownership of an experimental CAR‑T therapy for multiple myeloma as it readies a potential U.S. launch. Under the deal, Gilead paid $115 a share in cash plus a nontransferable $5 contingent value right tied to future sales, valuing Arcellx at about $7.8 billion at closing. The transaction gives Gilead full control of anitocabtagene autoleucel, or anito‑cel, a BCMA‑targeted CAR‑T therapy under regulatory review. ...